NCT04030338

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Serial PSMA PET Imaging in the Assessment of Treatment Response in Patients With Progressive Prostate Cancer

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 58 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) scans used in this study accurate and better at imaging participants' prostate cancer than the usual methods.

Conditions

• Prostate Cancer
• Prostate Neoplasm
• Prostate Adenocarcinoma
• Prostate Cancer Metastatic
• Metastatic Prostate Cancer

Interventions

Type	Name	Description
DRUG	18F-DCFPyL-iPSMA	Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
DRUG	68Ga-HBED-iPSMA	Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
DIAGNOSTIC_TEST	PET/CT scan	The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed

Timeline

• Start date: 2019-07-19
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2019-07-23
• Last updated: 2025-09-03

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study